Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

BACKGROUND: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicenter, observational study, in which, information of 388 patients randomly selected and treate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Neurol
Autors principals: Meca-Lallana, José, Ayuso, Teresa, Martínez-Yelamos, Sergio, Durán, Carmen, Contreras Martín, Yessica, Herrera Navarro, Nicolás, Pérez Sempere, Angel, Álvarez-Cermeño, Jose C., Millán Pascual, Jorge, Meca-Lallana, Virginia, Romero Sevilla, Raúl, Ricart, Javier
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2020
Matèries:
Clinical Neurology: Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265769/
https://ncbi.nlm.nih.gov/pubmed/32187609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000505778
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars